Search Results - "Quantin, X."

Effects of cigarette smoking on reproduction by Dechanet, C, Anahory, T, Mathieu Daude, J C, Quantin, X, Reyftmann, L, Hamamah, S, Hedon, B, Dechaud, H

“…BACKGROUND Cigarette smoking is associated with lower fecundity rates, adverse reproductive outcomes and a higher risk of IVF failures. Over the last few…”
Get full text

Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies by Solassol, J., Vendrell, J.A., Senal, R., Audran, P., Leenhardt, F., Quantin, X.

“…•Progression on osimertinib and re-responding to dabrafetinib/trametinib sequential treatment.•BRAF activating mutations in ctDNA reveal tumor clonal evolution…”
Get full text

Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors by Heudel, P.E., de Montfort, A., Debieuvre, D., Chouaid, C., Carton, M., Audigier-Valette, C., Filleron, T., Chabaud, S., Stancu, A., Quantin, X., Hiret, S., Bosquet, L., Blay, J.Y.

“…•This retrospective study included 10 796 AMLC patients allowed to demonstrate that the rate of SPCs is significantly lower on the group of patients treated…”
Get full text

RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection by Basse, C., Botticella, A., Molina, T.J., Falcoz, P.E., Oulkhouir, Y., Kerjouan, M., Pichon, E., Westeel, V., Thiberville, L., Quantin, X., Clément-Duchêne, C., Khalifa, J., Tinier, F. Le, Ginoux, M., Thillays, F., Mordant, P., Besse, B., Thomas, P.A., Péchoux, C. Le, Girard, Nicolas

“…Thymomas are rare intrathoracic malignancies that may be aggressive and difficult to treat. Knowledge and level of evidence for treatment strategies are mainly…”
Get full text

Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database by Girard, N., Pérol, M., Simon, G., Audigier Valette, C., Gervais, R., Debieuvre, D., Schott, R., Quantin, X., Coudert, B., Lena, H., Carton, M., Robain, M., Filleron, T., Chouaid, C.

Get full text

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations by Mazieres, J., Cropet, C., Montané, L., Barlesi, F., Souquet, P.J., Quantin, X., Dubos-Arvis, C., Otto, J., Favier, L., Avrillon, V., Cadranel, J., Moro-Sibilot, D., Monnet, I., Westeel, V., Le Treut, J., Brain, E., Trédaniel, J., Jaffro, M., Collot, S., Ferretti, G.R., Tiffon, C., Mahier-Ait Oukhatar, C., Blay, J.Y.

“…BRAF mutations occurring in 1%–5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact…”
Get full text

Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA) by Wislez, M., Blons, H., Domblides, C., Barlesi, F., Mazieres, J., Monnet, I., Kiakouama Maleka, L., Quantin, X., Taillade, L., Lena, H., Fraisse, P., Janicot, H., Audigier Valette, C., Amour, E., Langlais, A., Rabbe, N., Cadranel, J., Laurent puig, P., Lavolé, A.

Get full text

Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania by Rivet, V, Quantin, X, Faillie, J L, Lesage, C, Meunier, L, Faure, S, Hillaire-Buys, D, Lesouder, C, Fabre, S, Assenat, E, Rullier, P, Guilpain, P, Maria, A T J

“…Immune checkpoint inhibitors (ICIs) can cause numerous and complex immune-related adverse events whose management need a multidisciplinary approach. Herein, we…”
Get full text

Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial by Mazières, J., Montané, L., Barlesi, F., Quantin, X., Trédaniel, J., Le Treut, J., Avrillon, V., Lavolé, A., Westeel, V., Orsini Piocelle, F., Pichon, E., Thiberville, L., Borel, C., Renault, P.A., Jaffro, M., Collot, S., Ferretti, G., Legrand, F., Mahier Ait Oukhatar, C., Blay, J.Y.

Get full text

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort by Thomas, Q.D., Quantin, X., Lemercier, P., Chouaid, C., Schneider, S., Filleron, T., Remon-Masip, J., Perol, M., Debieuvre, D., Audigier-Valette, C., Justeau, G., Loeb, A., Hiret, S., Clement-Duchene, C., Dansin, E., Stancu, A., Pichon, E., Bosquet, L., Girard, N., Du Rusquec, P.

“…The RAS/MEK signaling pathway is essential in carcinogenesis and frequently altered in non-small-cell lung cancer (NSCLC), notably by KRAS mutations (KRASm)…”
Get full text

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin by Pujol, J.-L., Breton, J.-L., Gervais, R., Rebattu, P., Depierre, A., Morère, J.-F., Milleron, B., Debieuvre, D., Castéra, D., Souquet, P.-J., Moro-Sibilot, D., Lemarié, E., Kessler, R., Janicot, H., Braun, D., Spaeth, D., Quantin, X., Clary, C.

“…Background: This multicenter, randomized, phase III study compared the efficacy, including progression-free survival (PFS), and safety of gemcitabine–docetaxel…”
Get full text

EPA-0654 – Lack of inhibitory control predict relapse in people willing to stop smoking by Flaudias, V, Lopez-Castroman, J, Llorca, P.M, Schmitt, A, Perriot, J, Picot, M, Courtet, P, Quantin, X, Guillaume, S

“…Introduction Most patients (70%) discontinuing tobacco smoking will relapse within 6 months. A major challenge is the understanding of the processes involved…”
Get full text

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data by CHOMA, D, DAURES, J-P, QUANTIN, X, PUJOL, J. L

“…In lung cancer, DNA content abnormalities have been described as a heterogeneous spectrum of impaired tumour cell DNA histogram patterns. They are merged into…”
Get full text

Etoposide Plus Cisplatin With or Without the Combination of 4′-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study by Pujol, Jean-Louis, Daurès, Jean-Pierre, Rivière, Alain, Quoix, Elisabeth, Westeel, Virginie, Quantin, Xavier, Breton, Jean-Luc, Lemarié, Etienne, Poudenx, Michel, Milleron, Bernard, Moro, Denis, Debieuvre, Didier, Le Chevalier, Thierry

“…Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC). To determine whether drug…”
Get full text

Appropriate medication prescribing in older people by Blain, H, Rambourg, P, Le Quellec, A, Ayach, L, Biboulet, P, Bismuth, M, Blain, A, Boulenger, J-P, Celton, B, Combe, B, Dauvilliers, Y, Davy, J-M, Geny, C, Hemmi, P, Hillaire-Buys, D, Jalabert, A, Jung, B, Leclercq, F, Léglise, M-S, Morel, J, Mourad, G, Ponrouch, M-P, Puisieux, F, Quantin, X, Quéré, I, Renard, E, Ribstein, J, Roch-Torreilles, I, Rolland, Y, Rosant, D, Terminet, A, Thuret, R, Villiet, M, Deshormières, N, Bourret, R, Bousquet, J, Jonquet, O, Millat, B

“…Drug-induced adverse effects are one of the main avoidable causes of hospitalization in older people. Numerous lists of potentially inappropriate medications…”
Get full text

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors by JACOT, W, QUANTIN, X, BOHER, J-M, ANDRE, F, MOREAU, L, GAINET, M, DEPIERRE, A, QUOIX, E, LE CHEVALIER, T, PUJOL, J-L

“…A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic…”
Get full text

Smoking cessation in patients with lung cancer by Quantin, X, Stoebner-Delbarre, A, Guichenez, P, Pujol, J-L

“…Smoking cessation is an important part of the management of patients with lung cancer. Continued smoking has been found to diminish treatment efficacy, to…”
Get more information

1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients by Chouaid, C., Perualila, N., Debieuvre, D., Quantin, X., Diels, J., Rahhali, N., Toueg, R., Simon, G., Bosquet, L., Filleron, T.

Get full text

1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France by Debieuvre, D., Macouillard, P., Quantin, X., Berktas, M., Girard, N., Audigier Valette, C., Filleron, T., Musilli, S., Bosquet, L., Pérol, M.

Get full text

KEYNOTE-867: Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in Patients with Unresected Stage I or II Non–Small-Cell Lung Cancer (NSCLC) by Jabbour, S.K., Houghton, B., Robinson, A.G., Quantin, X., Wehler, T., Kowalski, D., Ahn, M.J., Erman, M., Giaccone, G., Borghaei, H., McLean, J., Xu, Y., Souza, F., Pall, G.

Get full text